A mix of mega-rounds and smaller seed financings show investment happening at both ends of the venture capital spectrum. In public company financings, Gilead prices $2bn note offering, Biogen secures $1.5bn for Reata deal, Inhibrx completes a $200m PIPE and the IPO market shows new signs of life.

Deal Snapshot: Gilead will collaborate with the start-up on the discovery and development of first-in-class targeted, multifunctional, conditional therapeutics.

Epigenomics has finally gained US FDA approval for its Epi proColon noninvasive colorectal cancer screening test, ending what has been a long, obstacle-filled journey for the German-US molecular diagnostics company.

UroSens Ltd. has developed a test that measures the presence of dividing cells in a urine sample, where there should be no dividing cells, and thus is indicative of cancer. The start-up's lead indication is bladder cancer, but it is exploring its use in other cancers, including prostate.